Health Authority Meeting Support
How we help with Health Authority Meeting Support
Building a collaborative relationship with the U.S. Food and Drug Administration (FDA) is an essential component of a robust product development strategy for sponsors intending to bring novel drugs, biologics, and/or devices to market. Fortunately, the FDA offers various opportunities for interaction and guidance throughout the development lifecycle. FDA meetings provide an opportunity for sponsors to educate the Agency about their product(s) and the corresponding development strategies.
In turn, these meetings allow sponsors to seek input regarding available data, discuss evolving regulatory requirements, and identify potential gaps in the overall product plan. These interactions are often an invaluable tool for de-risking product development, particularly for sponsors advancing highly complex product modalities and/or pursuing novel therapeutic targets.
We help you prepare for health authority meetings.
Type A: Meetings that are “necessary for an otherwise stalled product development program to proceed (a critical path meeting) or to address an important safety issue.”
Type B PreIND: The purpose is to obtain FDA feedback on the drug development program and de-risk any potential clinical hold issues during the FDA review of the IND.
Type B End of Phase: The purpose is to discuss and de-risk the study design for the next clinical trial and to ensure the CMC and nonclinical aspects of the program are in line with the FDA’s expectations for the next phase of development.
Type C: Considered the “catch-all” category and includes any meeting concerning the development and review of a product that does not fall within the scope of other meeting types.
Type D: New for PDUFA VII – Intended for follow-up on a limited number of topics and are useful for gaining additional clarification or negotiating a particular issue in a development program.
INTERACT: New for CDER for PDUFA VII – Now for both biologics and drugs. Useful for early-stage settings. Typically used for setting nonclinical and early CMC strategies and do not take the place of a
PreIND meeting. Pre-Sub: CDRH meeting that occurs most frequently. Opportunity to obtain FDA feedback before premarket submission and ask product development questions.
Oncology drug development is different from most drug development programs in other therapeutic areas, or at least, has been historically. While most drugs are evaluated in randomized dose-ranging trials prior to pursuing pivotal clinical studies, oncology drug development, by comparison, is often accelerated due to the life-threatening nature of most cancers and the inherent toxicity […]
Shawn Roach, one of Halloran’s Regulatory Chemistry, Manufacturing, and Controls (CMC) experts, was a panelist at the Advancing Drug Development Forum (ADDF) held in Boston on December 14, 2023. Shawn and his fellow panelists discussed the regulatory implications of the FDA Modernization Act 2.0. Passed about a year ago, the FDA Modernization Act 2.0 formally overturned […]
On September 29, 2023, the U.S. Food and Drug Administration (FDA) announced their proposed rule, “Medical Devices; Laboratory Developed Tests.” The rule, if finalized, would amend the Federal Food, Drug, and Cosmetic Act (FD&C Act) such that laboratory developed tests (LDTs) would be regulated as medical devices. The FDA is proposing a policy under which […]